{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:19:50Z","timestamp":1789903190586,"version":"4.0.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1093\/jac\/dkm467","type":"journal-article","created":{"date-parts":[[2007,12,10]],"date-time":"2007-12-10T20:26:11Z","timestamp":1197318371000},"page":"382-388","source":"Crossref","is-referenced-by-count":83,"title":["Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection"],"prefix":"10.1093","volume":"61","author":[{"given":"Raf","family":"De Jongh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Hens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Basma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Tulkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Carryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,12,10]]},"reference":[{"key":"key\n\t\t\t\t20170425174851_DKM467C1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of \u03b2-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20170425174851_DKM467C2","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1128\/AAC.36.12.2577","article-title":"Continuous infusion of \u03b2-lactam antibiotics","volume":"36","author":"Craig","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00044011-199918020-00006","article-title":"Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia","volume":"18","author":"Nicolau","year":"1999","journal-title":"Clin Drug Invest"},{"key":"key\n\t\t\t\t20170425174851_DKM467C4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0924-8579(01)00329-6","article-title":"Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia","volume":"17","author":"Nicolau","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170425174851_DKM467C5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00134-004-2171-2","article-title":"Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia","volume":"30","author":"Boselli","year":"2004","journal-title":"Intensive Care Med"},{"key":"key\n\t\t\t\t20170425174851_DKM467C6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.20.1.38","article-title":"BRL 17421, a novel \u03b2-lactam antibiotic, highly resistant to \u03b2-lactamases, giving high and prolonged serum levels in humans","volume":"20","author":"Slocombe","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj2930607","article-title":"Interactions between active-site-serine \u03b2-lactamases and compounds bearing a methoxy side chain on the \u03b1-face of the \u03b2-lactam ring: kinetic and molecular modelling studies","volume":"293","author":"Matagne","year":"1993","journal-title":"Biochem J"},{"key":"key\n\t\t\t\t20170425174851_DKM467C8","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkl043","article-title":"Activity of temocillin versus prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England","volume":"57","author":"Livermore","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/jac\/dkl046","article-title":"In vitro activity of temocillin against extended spectrum \u03b2-lactamase-producing Escherichia coli","volume":"57","author":"Rodriguez-Villalobos","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C10","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1128\/AAC.47.5.1522-1528.2003","article-title":"IMP-12, a new plasmid-encoded metallo-\u03b2-lactamase from a Pseudomonas putida clinical isolate","volume":"47","author":"Docquier","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C11","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1128\/AAC.45.9.2643-2647.2001","article-title":"Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients","volume":"45","author":"Servais","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C12","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1128\/AAC.46.8.2327-2332.2002","article-title":"Comparative stability studies of antipseudomonal \u03b2-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)","volume":"46","author":"Viaene","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkg134","article-title":"Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units","volume":"51","author":"Baririan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C14","doi-asserted-by":"publisher","DOI":"10.1002\/9783527617395","volume-title":"Monte Carlo Methods","author":"Kalos","year":"1986"},{"key":"key\n\t\t\t\t20170425174851_DKM467C15","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.48.12.4718-4724.2004","article-title":"Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation","volume":"48","author":"Lodise","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1128\/AAC.48.5.1713-1718.2004","article-title":"Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141","volume":"48","author":"Mouton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/AAC.28.5.597","article-title":"Determination of ticarcillin levels in serum by high-pressure liquid chromatography","volume":"28","author":"Shull","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C18","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A7","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"key\n\t\t\t\t20170425174851_DKM467C19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 5","key":"key\n\t\t\t\t20170425174851_DKM467C20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003495-198500295-00027","article-title":"Renal clearance of temocillin in volunteers","volume":"29","author":"Overbosch","year":"1985","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170425174851_DKM467C21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/jac\/47.4.500","article-title":"Use of the t>MIC to choose between different dosing regimens of \u03b2-lactam antibiotics","volume":"47","author":"Mouton","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clinthera.2005.06.013","article-title":"A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit","volume":"27","author":"Mouton","year":"2005","journal-title":"Clin Ther"},{"issue":"Suppl 5","key":"key\n\t\t\t\t20170425174851_DKM467C23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003495-198500295-00028","article-title":"Temocillin pharmacokinetics in normal and impaired renal function","volume":"29","author":"Hoffler","year":"1985","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170425174851_DKM467C24","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1128\/AAC.01586-06","article-title":"Concentration\u2013effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo","volume":"51","author":"Mouton","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6","key":"key\n\t\t\t\t20170425174851_DKM467C25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1469-0691.2005.01265.x","article-title":"Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations","volume":"11","author":"Andes","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170425174851_DKM467C26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF02148656","article-title":"Interpretive criteria for temocillin disk diffusion susceptibility testing","volume":"4","author":"Fuchs","year":"1985","journal-title":"Eur J Clin Microbiol"},{"key":"key\n\t\t\t\t20170425174851_DKM467C27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10096-007-0370-9","article-title":"In vitro activity of temocillin against prevalent extended-spectrum \u03b2-lactamases producing Enterobacteriaceae from Belgian intensive care units","volume":"26","author":"Glupczynski","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170425174851_DKM467C28","first-page":"2909","article-title":"Ceftazidime","author":"Anonymous","year":"2000","journal-title":"Pharmacop\u00e9e Europ\u00e9enne"},{"key":"key\n\t\t\t\t20170425174851_DKM467C29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/18.3.335","article-title":"Antibacterial activity of resolved temocillin epimers","volume":"18","author":"White","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0022-3476(86)80754-5","article-title":"Kinetics of antimicrobial activity","volume":"108","author":"Vogelman","year":"1986","journal-title":"J Pediatr"},{"key":"key\n\t\t\t\t20170425174851_DKM467C31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/AAC.41.4.733","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion","volume":"41","author":"Mouton","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jac\/48.2.325","article-title":"Serum pharmacokinetics and sputum penetration of amikacin 30 mg\/kg once daily and of ceftazidime 200 mg\/kg\/day as a continuous infusion in cystic fibrosis patients","volume":"48","author":"Byl","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/AAC.40.3.691","article-title":"Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections","volume":"40","author":"Benko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425174851_DKM467C34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1592\/phco.2006.26.1.129","article-title":"Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists","volume":"26","author":"Ambrose","year":"2006","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/61\/2\/382\/13758932\/dkm467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,5]],"date-time":"2019-05-05T17:10:22Z","timestamp":1557076222000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkm467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,10]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,12,10]]},"published-print":{"date-parts":[[2008,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkm467","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12,10]]}}}